BioInvent International
Develops first-in-class immuno-modulatory antibodies for cancer therapy.
BINV | ST
Overview
Corporate Details
- ISIN(s):
- SE0015244520
- LEI:
- 549300E7QRHEF2IJUY10
- Country:
- Sweden
- Address:
- C/O BioInvent International Aktiebolag, 223 70 Lund
- Website:
- https://www.bioinvent.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
BioInvent International is a clinical-stage biotechnology company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates from its proprietary antibody library. BioInvent's primary focus is advancing its diversified clinical pipeline, which features drug candidates targeting unique mechanisms of action and novel targets like FcγRIIb and TNFR2. The company manages its development risks through stringent portfolio management and strategic partnerships with major pharmaceutical firms to develop transformative treatments for cancer patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-03 15:00 |
Regulatory Filings
BioInvent presenterar uppdaterade fas 2a monoterapidata på ASH 2025 gällande BI…
|
Swedish | 83.1 KB | ||
| 2025-11-03 15:00 |
Regulatory Filings
BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combina…
|
English | 81.9 KB | ||
| 2025-11-03 15:00 |
Regulatory Filings
BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2…
|
English | 82.2 KB | ||
| 2025-11-03 15:00 |
Regulatory Filings
BioInvent kommer att presentera tidiga fas 2a-data på ASH 2025 från den pågåend…
|
Swedish | 81.9 KB | ||
| 2025-10-29 08:00 |
Quarterly Report
|
Swedish | 2.5 MB | ||
| 2025-10-29 08:00 |
Quarterly Report
|
English | 2.4 MB | ||
| 2025-09-02 10:10 |
Board/Management Information
BioInvent Announces Board of Directors Update
|
English | 67.9 KB | ||
| 2025-09-02 10:10 |
Board/Management Information
BioInvent offentliggör förändring i styrelsen
|
Swedish | 67.3 KB | ||
| 2025-08-26 08:30 |
Interim / Quarterly Report
|
Swedish | 3.1 MB | ||
| 2025-08-26 08:30 |
Interim / Quarterly Report
|
English | 3.0 MB | ||
| 2025-08-26 08:29 |
Regulatory Filings
BioInvent Announces Strategic Changes in Portfolio to Accelerate Lead Clinical …
|
English | 82.3 KB | ||
| 2025-08-26 08:29 |
Regulatory Filings
BioInvent gör strategiska portföljförändringar för att accelerera ledande klini…
|
Swedish | 82.1 KB | ||
| 2025-06-12 09:00 |
Earnings Release
BioInvent presenterar lovande fas 2a-monoterapidata för BI-1808 i CTCL på EHA 2…
|
Swedish | 82.1 KB | ||
| 2025-06-12 09:00 |
Regulatory Filings
BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at E…
|
English | 82.1 KB | ||
| 2025-05-27 14:00 |
M&A Activity
XOMA Royalty förvärvar mezagitamab royalty- och milstolpsrättigheter av BioInve…
|
Swedish | 89.3 KB |
Automate Your Workflow. Get a real-time feed of all BioInvent International filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioInvent International
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioInvent International via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-09 | Erik Esveld | Other | Buy | 4,000 | 70,960.00 SEK |
| 2023-06-30 | Sylvie Ryckebusch | Other | Buy | 5,000 | 7,890.00 EUR |
| 2022-11-16 | Dharminder Chahal | Other | Buy | 10,000 | 352,500.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 3,262 | 109,798.92 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 800 | 27,200.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 750 | 25,425.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 611 | 20,700.68 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 530 | 17,193.20 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 500 | 16,800.00 SEK |
| 2022-03-09 | Martin Welschof | Other | Buy | 400 | 13,712.00 SEK |
Peer Companies
